An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Clinical trial NCT05011851 · COMPLETED
Trial details
- NCT number
- NCT05011851
- Sponsor
- Neuren Pharmaceuticals Limited
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-12
- Primary completion
- 2024-05-13
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.